Esfam Biotech

Esfam is focused on world-first molecular research into the most significant diseases affecting global populations today.

In collaboration with industry-leading partners, our work targets major health and economic concerns. We can now announce significant discoveries in treatments for Long-COVID, advanced prostate cancer and a global viral infection affecting pigs (PRRS).

It is a privilege to bring new hope to millions.

Long-COVID: New treatment
discovery and development

Almost two years on from its first observation, SARS-CoV-2 remains a virus of critical concern at a global scale.

As vaccines progress, there remains no commercial treatment after the virus has been contracted. The impact of these symptoms can be devastating and life-long.

Esfam Biotech has discovered a panel of molecules which, after computer-based design of a virus-binding target on the cell, is believed to block the SARS-CoV-2 virus from damaging infected cells.

Already confirmed in cell-based studies and animal models, our development pathway will see us in human clinical trials by the end of 2024.

Breakthrough agriculture treatment

Porcine Respiratory and Reproductive Syndrome (PRRS) has a profound economic impact on agriculture, a significant industry in the global economy. Despite the development of short-lived vaccines, no specific treatments have been developed before now.

Our research has produced molecules that block the PRRS virus binding site in a cell-based assay. Further animal testing will allow us to bring this first-in-class therapy to market.

Fighting against advanced prostate cancer

Affecting around 1 in every 1000 Australian men, prostate cancer accounts for more than 10% of all male deaths from cancer. While it responds well to androgen-deprivation therapy, long-term options are limited.

Our world-first research focuses on a non-hormonal driver. We have revealed potent anti-cancer effects in cell and animal models against prostate cancers that do not respond to hormone blockade.

We are currently testing the molecules in animal models and commencing studies involving other types of cancer, with human trials to follow.

Sign up and keep up to date with our news, pipeline and investors

By clicking “subscribe” you accepting to receive newsletters from Esfam Biotech.